

NA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 291 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America Kidney Cancer Diagnostics Market is projected to register a CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

North America Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:

- Rising healthcare expenditure for better health services
- Increase in diagnostic procedure for kidney cancer
- Growing prevalence of kidney cancer

Market Players

Some of the key market players for North America kidney cancer diagnostics market are listed below:

- Ambry Genetics
- BD
- Blueprint Oy.
- Canon Medical Systems Corporation
- CD Genomics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- CENTOGENE N.V.
- Creative Diagnostics
- FUJIFILM Corporation
- GeneDx, LLC
- GenPath
- Grail
- Illumina, Inc.
- Invitae Corporation
- Koninklijke Philips N.V.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Qiagen
- Seimens Healthcare GmbH
- Thermo Fisher Scientific

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	84
1.1 OBJECTIVES OF THE STUDY	84
1.2 MARKET DEFINITION	84
1.3 OVERVIEW OF THE NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET	84
1.4 CURRENCY AND PRICING	86
1.5 LIMITATIONS	87
1.6 MARKETS COVERED	87
2 MARKET SEGMENTATION	91
2.1 MARKETS COVERED	91
2.2 GEOGRAPHICAL SCOPE	92
2.3 YEARS CONSIDERED FOR THE STUDY	93
2.4 DBMR TRIPOD DATA VALIDATION MODEL	94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	97
2.6 MULTIVARIATE MODELLING	98
2.7 MARKET APPLICATION COVERAGE GRID	99
2.8 TEST TYPE LIFELINE CURVE	100
2.9 DBMR MARKET POSITION GRID	101
2.10 VENDOR SHARE ANALYSIS	102
2.11 SECONDARY SOURCES	103
2.12 ASSUMPTIONS	103
3 EXECUTIVE SUMMARY	104
4 PREMIUM INSIGHTS	107
4.1 PESTEL ANALYSIS	108
4.2 PORTER'S 5 FORCES	109
4.3 EPIDEMIOLOGY	110
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES	111
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES	111

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5	INDUSTRY INSIGHTS	112
6	NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS	114
7	MARKET OVERVIEW	117
7.1	DRIVERS	119
7.1.1	GROWING PREVALENCE OF KIDNEY CANCER	119
7.1.2	INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER	121
7.1.3	RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT	122
7.1.4	RIISING AWARENESS TOWARDS KIDNEY CANCER	122
7.2	RESTRAINTS	123
7.2.1	STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS	123
7.2.2	TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS	124
7.3	OPPORTUNITIES	124
7.3.1	RIISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	124
7.3.2	GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS	125
7.3.3	GROWING DEMAND FOR BETTER QUALITY HEALTHCARE	125
7.3.4	INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	126
7.4	CHALLENGES	126
7.4.1	LACK OF SKILLED AND CERTIFIED PROFESSIONALS	126
7.4.2	HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS	127
8	NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE	128
8.1	OVERVIEW	129
8.2	IMAGING	133
8.2.1	COMPUTED TOMOGRAPHY	134
8.2.2	ULTRASOUND	134
8.2.3	MAGNETIC RESONANCE IMAGING (MRI)	134
8.2.4	ANGIOGRAPHY	134
8.2.5	X-RAY	134
8.2.6	OTHERS	134
8.3	BLOOD TEST	134
8.4	BIOPSY	135
8.4.1	FINE NEEDLE ASPIRATION	136
8.4.2	NEEDLE CORE BIOPSY	136
8.5	BIOMARKER TEST	136
8.5.1	AQUAPORIN 1 (AQP1)	138
8.5.2	PERILIPIN (PLIN2)	138
8.5.3	N-METHYLTRANSFERASE (NMNT)	138
8.5.4	L-PLASTIN (LCP-1)	138
8.5.5	NM23A	138
8.6	GENETIC TEST	138
8.7	OTHERS	139
9	NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE	141
9.1	OVERVIEW	142
9.2	STAGE I	145
9.3	STAGE II	145
9.4	STAGE III	146
9.5	STAGE IV	147

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148

10.1 OVERVIEW 149

10.2 RENAL CELL CARCINOMA 153

10.2.1 IMAGING 154

10.2.2 BLOOD TEST 154

10.2.3 BIOPSY 154

10.2.4 BIOMARKER TEST 154

10.2.5 GENETIC TEST 154

10.2.6 OTHERS 154

10.3 CLEAR CELL RENAL CELL CARCINOMA 154

10.3.1 IMAGING 156

10.3.2 BLOOD TEST 156

10.3.3 BIOPSY 156

10.3.4 BIOMARKER TEST 156

10.3.5 GENETIC TEST 156

10.3.6 OTHERS 156

10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156

10.4.1 PAPILLARY RENAL CELL CARCINOMA 157

10.4.1.1 IMAGING 158

10.4.1.2 BLOOD TEST 158

10.4.1.3 BIOPSY 158

10.4.1.4 BIOMARKER TEST 158

10.4.1.5 GENETIC TEST 158

10.4.1.6 OTHERS 158

10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158

10.4.2.1 IMAGING 159

10.4.2.2 BLOOD TEST 159

10.4.2.3 BIOPSY 159

10.4.2.4 BIOMARKER TEST 159

10.4.2.5 GENETIC TEST 159

10.4.2.6 OTHERS 159

11 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160

11.1 OVERVIEW 161

11.2 INSTRUMENT BASED PRODUCTS 165

11.2.1 IMAGING 166

11.2.2 BIOPSY 166

11.3 PLATFORM BASED PRODUCTS 166

11.3.1 NEXT GENERATION SEQUENCING 168

11.3.2 MICROARRAYS 168

11.3.3 PCR 169

11.3.4 OTHERS 169

11.4 KITS AND REAGENTS 169

11.4.1 RENAL CANCER PANELS 171

11.4.2 RENAL CANCER ANTIBODIES 171

11.5 OTHER CONSUMABLES 171

12 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172

12.1 OVERVIEW 173

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.2 FLUORESCENT IN SITU HYBRIDIZATION	176
12.3 NEXT GENERATION SEQUENCING	176
12.4 FLUORIMMUNOASSAY	177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION	178
12.6 IMMUNOHISTOCHEMICAL	179
12.7 OTHERS	179
13 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION	181
13.1 OVERVIEW	182
13.2 SCREENING	185
13.2.1 INSTRUMENT BASED PRODUCTS	186
13.2.2 PLATFORM BASED PRODUCTS	186
13.2.3 KITS AND REAGENTS	186
13.2.4 OTHER CONSUMABLES	186
13.3 DIAGNOSTIC AND PREDICTIVE	186
13.3.1 INSTRUMENT BASED PRODUCTS	187
13.3.2 PLATFORM BASED PRODUCTS	187
13.3.3 KITS AND REAGENTS	187
13.3.4 OTHER CONSUMABLES	187
13.4 PROGNOSTIC	188
13.4.1 INSTRUMENT BASED PRODUCTS	189
13.4.2 PLATFORM BASED PRODUCTS	189
13.4.3 KITS AND REAGENTS	189
13.4.4 OTHER CONSUMABLES	189
13.5 RESEARCH	189
13.5.1 INSTRUMENT BASED PRODUCTS	190
13.5.2 PLATFORM BASED PRODUCTS	190
13.5.3 KITS AND REAGENTS	190
13.5.4 OTHER CONSUMABLES	191
14 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER	192
14.1 OVERVIEW	193
14.2 HOSPITALS	196
14.3 DIAGNOSTIC CENTERS	196
14.4 CANCER RESEARCH CENTERS	197
14.5 ACADEMIC INSTITUTES	198
14.6 AMBULATORY SURGICAL CENTERS	198
14.7 OTHERS	199
15 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	200
15.1 OVERVIEW	201
15.2 DIRECT TENDER	204
15.3 RETAIL SALES	204
15.4 OTHERS	205
16 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION	206
16.1 NORTH AMERICA	207
16.1.1 U.S.	221
16.1.2 CANADA	230
16.1.3 MEXICO	239
17 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE	248

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	248
18 SWOT ANALYSIS	249
19 COMPANY PROFILE	250
19.1 CANON MEDICAL SYSTEMS CORPORATION	250
19.1.1 COMPANY SNAPSHOT	250
19.1.2 REVENUE ANALYSIS	250
19.1.3 COMPANY PROFILE	251
19.1.4 PRODUCT PORTFOLIO	251
19.1.5 RECENT DEVELOPMENT	251
19.2 KONINKLIJKE PHILIPS N.V.	252
19.2.1 COMPANY SNAPSHOT	252
19.2.2 REVENUE ANALYSIS	252
19.2.3 COMPANY PROFILE	253
19.2.4 PRODUCT PORTFOLIO	253
19.2.5 RECENT DEVELOPMENTS	254
19.3 GENERAL ELECTRIC COMPANY	255
19.3.1 COMPANY SNAPSHOT	255
19.3.2 REVENUE ANALYSIS	255
19.3.3 COMPANY PROFILE	256
19.3.4 PRODUCT PORTFOLIO	256
19.3.5 RECENT DEVELOPMENTS	257
19.4 SIEMENS HEALTHCARE GMBH	258
19.4.1 COMPANY SNAPSHOT	258
19.4.2 REVENUE ANALYSIS	258
19.4.3 COMPANY PROFILE	259
19.4.4 PRODUCT PORTFOLIO	259
19.4.5 RECENT DEVELOPMENT	260
19.5 GRAIL	261
19.5.1 COMPANY SNAPSHOT	261
19.5.2 PRODUCT PORTFOLIO	261
19.5.3 RECENT DEVELOPMENTS	261
19.6 AMBRY GENETICS	263
19.6.1 COMPANY SNAPSHOT	263
19.6.2 PRODUCT PORTFOLIO	263
19.6.3 RECENT DEVELOPMENT	263
19.7 BIOVENDOR R&D	264
19.7.1 COMPANY SNAPSHOT	264
19.7.2 PRODUCT PORTFOLIO	264
19.7.3 RECENT DEVELOPMENT	264
19.8 BLUEPRINT GENETICS OY.	265
19.8.1 COMPANY SNAPSHOT	265
19.8.2 PRODUCT PORTFOLIO	265
19.8.3 RECENT DEVELOPMENT	265
19.9 CD GENOMICS	266
19.9.1 COMPANY SNAPSHOT	266
19.9.2 PRODUCT PORTFOLIO	266
19.9.3 RECENT DEVELOPMENT	266

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.10	CENTOGENE N.V.	267
19.10.1	COMPANY SNAPSHOT	267
19.10.2	REVENUE ANALYSIS	267
19.10.3	PRODUCT PORTFOLIO	268
19.10.4	RECENT DEVELOPMENT	268
19.11	CREATIVE DIAGNOSTICS	269
19.11.1	COMPANY SNAPSHOT	269
19.11.2	PRODUCT PORTFOLIO	269
19.11.3	RECENT DEVELOPMENT	269
19.12	FUJIFILM CORPORATION	270
19.12.1	COMPANY SNAPSHOT	270
19.12.2	REVENUE ANALYSIS	270
19.12.3	PRODUCT PORTFOLIO	271
19.12.4	RECENT DEVELOPMENTS	271
19.13	GENEDX, LLC	272
19.13.1	COMPANY SNAPSHOT	272
19.13.2	REVENUE ANALYSIS	272
19.13.3	PRODUCT PORTFOLIO	273
19.13.4	RECENT DEVELOPMENT	273
19.14	GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY	274
19.14.1	COMPANY SNAPSHOT	274
19.14.2	PRODUCT PORTFOLIO	274
19.14.3	RECENT DEVELOPMENT	274
19.15	ILLUMINA, INC.	275
19.15.1	COMPANY SNAPSHOT	275
19.15.2	REVENUE ANALYSIS	275
19.15.3	PRODUCT PORTFOLIO	276
19.15.4	RECENT DEVELOPMENT	276

NA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 291 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-26"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com